CN108156807A - 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 - Google Patents

含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 Download PDF

Info

Publication number
CN108156807A
CN108156807A CN201680031203.4A CN201680031203A CN108156807A CN 108156807 A CN108156807 A CN 108156807A CN 201680031203 A CN201680031203 A CN 201680031203A CN 108156807 A CN108156807 A CN 108156807A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
rosuvastatin
acceptable salt
losartan
amlodipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680031203.4A
Other languages
English (en)
Chinese (zh)
Inventor
金用镒
林昊泽
曺赫俊
尹英洙
朴宰贤
禹钟守
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Priority to CN202110171819.4A priority Critical patent/CN112933093A/zh
Publication of CN108156807A publication Critical patent/CN108156807A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201680031203.4A 2015-06-30 2016-06-29 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 Pending CN108156807A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110171819.4A CN112933093A (zh) 2015-06-30 2016-06-29 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0093714 2015-06-30
KR20150093714 2015-06-30
PCT/KR2016/006977 WO2017003186A1 (en) 2015-06-30 2016-06-29 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110171819.4A Division CN112933093A (zh) 2015-06-30 2016-06-29 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂

Publications (1)

Publication Number Publication Date
CN108156807A true CN108156807A (zh) 2018-06-12

Family

ID=57608904

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110171819.4A Pending CN112933093A (zh) 2015-06-30 2016-06-29 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
CN201680031203.4A Pending CN108156807A (zh) 2015-06-30 2016-06-29 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110171819.4A Pending CN112933093A (zh) 2015-06-30 2016-06-29 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂

Country Status (6)

Country Link
KR (2) KR20170003459A (es)
CN (2) CN112933093A (es)
MX (2) MX2017014311A (es)
PH (1) PH12017501986A1 (es)
RU (1) RU2724338C2 (es)
WO (1) WO2017003186A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113747885A (zh) * 2019-04-18 2021-12-03 韩美药品株式会社 包含依泽替米贝和氯沙坦的药物组合制剂
CN116018137A (zh) * 2020-08-25 2023-04-25 株式会社大熊制药 用于治疗或预防高血压和高血脂症的单一剂型的药物组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019022436A2 (ko) * 2017-07-27 2019-01-31 에리슨제약(주) Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물
KR20190043076A (ko) * 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
CN108245516B (zh) * 2017-11-09 2019-04-12 浙江京新药业股份有限公司 一种含瑞舒伐他汀钙的药物组合物及其制备方法
CN109464407A (zh) * 2018-12-27 2019-03-15 成都恒瑞制药有限公司 瑞舒伐他汀钙快速释放制剂及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268053A (zh) * 1997-08-29 2000-09-27 辉瑞大药厂 包含阿伐他汀和抗高血压药的联合疗法
US20030124191A1 (en) * 2001-12-27 2003-07-03 Jerome Besse Use of an immediate-release powder in pharmaceutical and nutraceutical compositions
CN101090718A (zh) * 2004-12-30 2007-12-19 韩美药品株式会社 3－羟基－3－甲基戊二酰辅酶a还原酶抑制剂和抗高血压剂的复合剂型及其制备方法
US20100074951A1 (en) * 2006-10-30 2010-03-25 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN102292070A (zh) * 2009-01-23 2011-12-21 韩美控股株式会社 具有提高的稳定性的包含氨氯地平和氯沙坦的固体药物组合物
WO2013154390A1 (en) * 2012-04-13 2013-10-17 Hanmi Pharm. Co., Ltd. Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same
WO2015080433A1 (en) * 2013-11-29 2015-06-04 Hanmi Pharm. Co., Ltd. Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268053A (zh) * 1997-08-29 2000-09-27 辉瑞大药厂 包含阿伐他汀和抗高血压药的联合疗法
US20030124191A1 (en) * 2001-12-27 2003-07-03 Jerome Besse Use of an immediate-release powder in pharmaceutical and nutraceutical compositions
CN101090718A (zh) * 2004-12-30 2007-12-19 韩美药品株式会社 3－羟基－3－甲基戊二酰辅酶a还原酶抑制剂和抗高血压剂的复合剂型及其制备方法
US20100074951A1 (en) * 2006-10-30 2010-03-25 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
CN102292070A (zh) * 2009-01-23 2011-12-21 韩美控股株式会社 具有提高的稳定性的包含氨氯地平和氯沙坦的固体药物组合物
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
WO2013154390A1 (en) * 2012-04-13 2013-10-17 Hanmi Pharm. Co., Ltd. Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same
WO2015080433A1 (en) * 2013-11-29 2015-06-04 Hanmi Pharm. Co., Ltd. Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李全林: "《新医药开发与研究 下册》", 31 December 2008, 中国医药科技出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113747885A (zh) * 2019-04-18 2021-12-03 韩美药品株式会社 包含依泽替米贝和氯沙坦的药物组合制剂
CN113747885B (zh) * 2019-04-18 2023-08-15 韩美药品株式会社 包含依泽替米贝和氯沙坦的药物组合制剂
TWI827828B (zh) * 2019-04-18 2024-01-01 南韓商韓美藥品股份有限公司 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑
CN116018137A (zh) * 2020-08-25 2023-04-25 株式会社大熊制药 用于治疗或预防高血压和高血脂症的单一剂型的药物组合物

Also Published As

Publication number Publication date
KR20180044873A (ko) 2018-05-03
RU2018103213A3 (es) 2019-12-09
WO2017003186A1 (en) 2017-01-05
KR20170003459A (ko) 2017-01-09
RU2724338C2 (ru) 2020-06-23
MX2017014311A (es) 2018-03-07
CN112933093A (zh) 2021-06-11
PH12017501986A1 (en) 2018-03-19
MX2021005210A (es) 2021-06-18
RU2018103213A (ru) 2019-07-31

Similar Documents

Publication Publication Date Title
CN108156807A (zh) 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
US20200375968A1 (en) Apixaban formulations
TWI649099B (zh) 包含氨氯地平（ａｍｌｏｄｉｐｉｎｅ）、洛沙坦（ｌｏｓａｒｔａｎ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）之藥學組合物配方
EP2413931B1 (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
CN101528203B (zh) 用于基于择时治疗理论治疗心血管疾病的联合制剂
RU2298418C2 (ru) Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
MX2008016099A (es) Composicion farmaceutica que comprende amlodipina y losartan.
CA2586760A1 (en) Stabilized ramipril compositions and methods of making
EP3320903B1 (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin
CN102335176B (zh) 一种口服固体药用组合物及其制备方法
CN108289850B (zh) 含有氨氯地平、氯沙坦和氯噻酮的药物复合制剂
CA2628955A1 (en) Compositions of stabilized ramipril in combination with another active agent
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
JP4165224B2 (ja) 発泡性組成物
US20160045497A1 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CN102316856A (zh) 药物制剂
TWI827828B (zh) 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑
WO2024109927A1 (zh) 包含美阿沙坦钾与钙通道阻滞剂的药物组合物，及其制备方法及应用
TWI734046B (zh) 包含替米沙坦或其藥學上可接受鹽類之具有改良的吸濕性質和溶解速率之製劑
TW202432121A (zh) 包含美阿沙坦鉀與鈣通道阻滯劑的藥物組合物、及其製備方法及用途
TWI503119B (zh) 含有氨氯地平（ａｍｌｏｄｉｐｉｎｅ）及洛沙坦（ｌｏｓａｒｔａｎ）之固體藥學組成物及其製造方法
BR112015022000B1 (pt) Preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180612